Please use this identifier to cite or link to this item:
Title: Therapeutics for rheumatic fever and rheumatic heart disease.
Authors: Ralph AP
Currie BJ
Citation: (c) NPS MedicineWise.
Aust Prescr. 2022 Aug;45(4):104-112. doi: 10.18773/austprescr.2022.034. Epub 2022 Aug 1.
Abstract: The goals of acute rheumatic fever therapy are to relieve symptoms, mitigate cardiac valve damage and eradicate streptococcal infection. Preventing future recurrences requires long-term secondary antibiotic prophylaxis and ongoing prevention of Streptococcus pyogenes (group A streptococcus) infections The recommended regimen for secondary prophylaxis comprises benzathine benzylpenicillin G intramuscular injections every four weeks. For patients with non-severe or immediate penicillin hypersensitivity, use erythromycin orally twice daily The goals of therapy for rheumatic heart disease are to prevent progression and optimise cardiac function. Secondary antibiotic prophylaxis can reduce the long-term severity of rheumatic heart disease Patients with rheumatic heart disease, including those receiving benzathine benzylpenicillin G prophylaxis, should receive amoxicillin prophylaxis before undergoing high-risk dental or surgical procedures. If they have recently been treated with a course of penicillin or amoxicillin, or have immediate penicillin hypersensitivity, clindamycin is recommended.
Click to open Pubmed Article:
Journal title: Australian prescriber
Volume: 45
Pages: 104-112
Publication Date: 2022
Type: Journal Article
Journal Article
DOI: 10.18773/austprescr.2022.034
Orcid: 0000-0002-2253-5749
Appears in Collections:(a) NT Health Research Collection

Files in This Item:
There are no files associated with this item.

Items in ePublications are protected by copyright, with all rights reserved, unless otherwise indicated.

Google Media

Google ScholarTM

Who's citing


PubMed References

Who's citing